On July 1, 2018, the University of Rochester, Department of Neurology received a 5-year renewal to remain as a clinical research site within the NINDS funded Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). The University of Rochester was an inaugural site of the NeuroNEXT Network beginning in 2011. During the 7 years of funding, we have been a study site for seven of the nine trials run through the Network. Please see the NeuroNEXT website for more information about the UR NEXT site.
The goal of NeuroNEXT Network is to conduct efficient Phase II studies of treatments for neurological disease through partnerships with academia, private foundations and industry. NeuroNEXT provides a robust standardized and accessible infrastructure to facilitate the rapid development and implementation of protocols in neurological disorders, in both adult and pediatric populations. As one of the 25 clinical sites spread across the United States, our site will have the opportunity to propose and participate in Phase II Clinical Trials targeted at a variety of neurologic disorders over the next five years. NeuroNEXT also presents a rich environment for early stage investigators to develop additional research and clinical trial skills that are critical for pursuing careers in academic clinical research. To this end, the Network includes a new initiative to provide a one-year research experience and Career Enhancement Fellowship opportunity to early stage investigators.